Clinical experience with montelukast plus ICS vs. only ICS in non-asthmatic eosinophilic bronchitis (NAEB) in Indian patients

Kshitij Mandke (Surat, India), Kshitij Mandke, Anup Mandke

Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma
Session: Pharmacological intervention in humans and murine models of asthma
Session type: Thematic Poster
Number: 1113
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Kshitij Mandke (Surat, India), Kshitij Mandke, Anup Mandke. Clinical experience with montelukast plus ICS vs. only ICS in non-asthmatic eosinophilic bronchitis (NAEB) in Indian patients. Eur Respir J 2016; 48: Suppl. 60, 1113

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Patients with allergic and eosinophilic asthma in the German severe asthma registry
Source: International Congress 2015 – Asthma and lung immunology
Year: 2015


Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy
Source: International Congress 2016 – Clinical and molecular studies in asthma
Year: 2016


FeNO in children with asthma is related to inhaled corticosteroids adherence, not to asthma control
Source: International Congress 2014 – Paediatric asthma: markers and molecules
Year: 2014

Asthma control with omalizumab treatment in severe allergic asthma and severe non-allergic asthma patients
Source: International Congress 2015 – Asthma and lung immunology
Year: 2015

Efficacy of omalizumab in allergic asthma by asthma severity and eosinophilic status
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015


Sputum eosinophilia in severe allergic asthma is not a reliable marker of omalizumab treatment
Source: International Congress 2015 – Immune mechanisms in the human lung
Year: 2015


Study of some inflammatory markers in children with moderate persistent bronchial asthma before and after therapy with inhaled corticosteroids
Source: Annual Congress 2013 –Monitoring asthma: genes, cells and molecules
Year: 2013

Combined therapy of asthma and allergic rhinitis
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013


Airway hyperresponsiveness (AHR) to mannitol following regular inhaled corticosteroids (ICS) in Australian army and police recruits
Source: International Congress 2015 – Exploring mechanisms in obstructive airway diseases
Year: 2015


Chronic rhinosinusitis with and without nasal polyps and rhinitis in adult asthma. Frequency distribution and relationship with asthma control and severity (the IRIS-ASMA study)
Source: Annual Congress 2013 –Comorbidities and respiratory disease and late-breaking abstracts
Year: 2013


Airway hyperresponsiveness in patients treated with omalizumab
Source: International Congress 2015 – Immune mechanisms in the human lung
Year: 2015


When needed use of inhaled steroids in children with asthma
Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management
Year: 2014

Response to inhaled corticosteroids in patients with non-asthmatic eosinophilic bronchitis
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020


Sputum microbiota in Chinese adults with eosinophilic versus non-eosinophilic asthma
Source: International Congress 2015 – Clincal aspects of asthma: monitoring and mechanisms
Year: 2015


Effect of cromolyn inhaler on resistant neutrophilic cough variant of asthma, A phase two clinical trial
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014


Treatment of asthma the current European perspective
Source: Annual Congress 2006 - Childhood asthma therapy: where we are now and where we need to go
Year: 2006


Pattern of asthma control and inhaled corticosteroid (ICS) use in an Australian asthma population
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013


Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study
Source: International Congress 2016 – Asthma points to ponder
Year: 2016

Long-term using of omalizumab in children with atopic severe persistent non-controlled asthma
Source: Annual Congress 2013 –Uncontrolled and severe asthma in children
Year: 2013

Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma
Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management
Year: 2014